Tisdag 3 Februari | 04:09:54 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-01-12 - Extra Bolagsstämma 2026
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-29 21:43:00

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 29 January 2026 – Circio Holding ASA (OSE: CRNA) a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces preliminary results of the rights issue of up to NOK 50 million in gross proceeds (the “Rights Issue”).

The subscription period for the Rights Issue expired today, 29 January 2026, at 16:30 CET. The Rights Issue attracted strong interest from existing and new investors and was oversubscribed by more than 50%. As approved by the EGM on 12 January 2026, to cover all pre-subscriptions in full a private placement of approximately NOK 15 million will be executed in parallel with the Rights Issue. This will bring the total gross proceeds from the transactions to approximately NOK 65 million.

"The high demand for participation in the rights issue is a direct result of the technological breakthroughs Circio made during 2025, which led to a fully funded R&D collaboration with a global pharmaceutical company," said Damian Marron, Chair of the Board of Directors of Circio. "This new capital puts Circio in a robust financial position and will enable us to accelerate the circVec R&D activities and strengthen our scientific team in Stockholm. Combined with the rich pipeline of upcoming development milestones, we are now very well positioned to build further value for all our stakeholders in 2026".

The Rights Issue was led by long-term shareholders Høse AS, Star Kapital AS and Bækkelaget Holding AS, who jointly subscribed for approximately 30% of the Rights Issue. Members of Circio's board of directors and management jointly subscribed for approximately NOK 1.8 million, including NOK 400,000 from CEO, Dr. Erik Digman Wiklund.

"With strong support from both existing and new shareholders and Board and management, Circio now takes the next step on the journey to build the leading circular RNA expression platform company," said Dr. Erik Digman Wiklund, CEO of Circio. "The NOK 65 million raised in the oversubscribed transactions secure funding well into 2027, and the associated warrant structure is expected to prolong our financial runway to the second half of 2027. This strengthened foundation allows me and the talented Circio team to fully focus on further enhancing the circVec platform, forging novel partnerships and advancing our in-house programs in gene and cell therapy towards the clinic.”

The Rights Issue raises NOK 50 million in gross proceeds by issuance of 50,000,000 offer shares (the "Offer Shares"), at a subscription price of NOK 1.00 per share. The Rights Issue was 88.4% covered at launch by pre-subscriptions of NOK 24.2 million (48.4%) and a guarantee undertaking of NOK 20 million (40%). Subscribers in the Rights Issue will, without additional consideration, receive one warrant (the "Warrants") for every Offer Share allocated and paid by them.

The final allocation of the Offer Shares will take place tomorrow, on 30 January 2026, in accordance with the allocation criteria set out in the resolution made by the general meeting on 12 January 2026 and the securities note dated 13 January 2026 (the “Securities Note”, and together with a registration document dated on 1 October 2025, a registration document supplement and summary dated on 13 January 2026, the “Prospectus”). The Prospectus is available on the Company's website: https://www.circio.com/en/rightsissue2026/.

The final result of the Rights Issue, as well as information relating to the parallel private placement, will be published shortly thereafter. Final allocation of Offer Shares and the corresponding subscription amount to be paid by each subscriber, are expected to be available during the course of tomorrow, on 30 January 2026.

The payment date for the Offer Shares is 3 February 2026.